Background: Zoptarelin doxorubicin (AEZS-108, ) is an luteinising hormone-releasing hormone (LHRH)-cytotoxic hybrid drug consisting of an agonist coupled to the cytotoxic radical, doxorubicin. Methods: This is a single case report of a 66-year-old male who was Compliance with Ethics Guidelines: All procedures were followed in accordance with the responsible committee on human experimentation and with the Helsinki Declaration of 1975 and subsequent revisions. Informed consent was received from the patient involved in this case study.
It was estimated that more than 429,000 new cases of urothelial cancer (UC) were diagnosed worldwide in 2012. 1 There are limited treatments for locally advanced, unresectable, metastatic, platinum refractory UC. 2 As a single agent, doxorubicin has a response rate of 17 % in patients with previously treated and untreated advanced bladder cancer. Complete responses (CRs) are uncommon and the median duration of response was only 3 to 4 months. [3] [4] [5] [6] Luteinising hormone-releasing hormone receptors (LHRH-Rs) are found on human cells of urothelial origin. Their high expression on the neoplastic cells and minimal expression in non-neoplastic cells, makes the LHRH-R an attractive therapeutic target. 7, 8 Zoptarelin doxorubicin is an LHRH-cytotoxic hybrid drug, in which an LHRH agonist is coupled to the cytotoxic radical, doxorubicin. The binding permits zoptarelin doxorubicin to accumulate on the surface of cells expressing LHRH-R allowing the uptake of the doxorubicin, thereby exploiting these receptors to gain access to the targeted tumour cells.
Once internalised, the cytotoxic properties of doxorubicin provoke the anti-tumour response. 9, 10 Phase I and II studies of zoptarelin doxorubicin have been reported in females with LHRH-R-positive endometrial and ovarian cancer and have demonstrated that this drug has activity and can be safely given with few side effects. 11, 12 The first phase I study with zoptarelin doxorubicin included 17 women with epithelial cancers of ovary, endometrium or breast, and which were unresectable or metastatic. Each patient received intravenous doses of 10, 20, 40 In a recent phase I study, zoptarelin doxorubicin was a tolerable agent with activity in men with castration-and taxane-resistant prostate cancer.
The dose for further study in this patient population was recommended to be 210 mg/m 2 given intravenously every 3 weeks. NCT01234519, Study ID Number: AEZS-108-046). Inclusion criteria for the study were:
• Histologically or cytologically confirmed locally advanced or metastatic UC Eastern Cooperative Oncology Group (ECOG) status of 0, 1 or 2 patients with measurable disease and documented progression on at least one prior chemotherapy regimen, which must have incorporated platinum-based therapy.
• Expression of LHRH receptors confirmed by immunohistochemistry on archival cancer tissue.
• Left ventricular ejection fraction (LVEF) >50 %. Figure 2) . CR was evident at 20 months posttreatment (see Figure 3 ). Thirty months (2.5 years) after starting treatment the patient is asymptomatic with no evidence of disease.
Case Report

Discussion
The standard chemotherapy treatment for advanced disease in patients with UC has been cisplatin-based and with a median survival of 15 months. Unfortunately, long-term survival has been suboptimal -most patients die from their disease. [15] [16] [17] Once the cancer progresses after firstline cisplatin-based therapy, there are limited good treatment options.
The average median overall survival of these patients is 6-9 months. 2, 3, [18] [19] [20] A randomised phase III trial with 370 patients compared vinflunine (VFL) plus best supportive care (BSC) with BSC alone as second-line therapy.
In the eligible population, the median overall survival was significantly longer for VFL + BSC than BSC (6.9 versus 4.3 months, respectively). As a result of this study, VFL was the first agent to be approved in Europe for second-line treatment in UC. 21, 22 Doxorubicin, a DNA-intercalating antibiotic, has been used alone, as first-line therapy in advanced UC patients, and in combination with other agents as second-line therapy, with a 17 % response rate. [3] [4] [5] [6] Zoptarelin doxorubicin, an LHRH-cytotoxic hybrid drug whose rational design covalently couples the carrier D-Lys6-LHRH (an LHRH agonist)
to the doxorubicin radical, employs the doxorubicin molecule as its cytotoxic agent. The structure of zoptarelin doxorubicin fully preserves the cytotoxicity of doxorubicin while maintaining the binding affinity of the LHRH carrier. 11 As receptors for LHRH are not expressed in high concentrations in most normal tissues, serious targeting related side effects are not expected after treatment with zoptarelin doxorubicin. [23] [24] [25] LHRH-Rs have been reported in UC 7, 26 -zoptarelin doxorubicin powerfully inhibited growth of bladder cancer in nude mice. Zoptarelin doxorubicin exerted a greater effect than doxorubicin alone but with less toxicity. 26 Clinical activity and favourable safety have been obtained in patients with LHRH-R positive ovarian, endometrial cancer and prostate cancer. [11] [12] [13] [14] Ours is the first patient with LHRH-R-positive UC treated with zoptarelin doxorubicin that has been reported. 27 Despite failing multiple prior chemotherapies this patient had a CR with a long progression-free survival. Patient is still free of disease at 30 months.
The phase I study is completed and closed to accrual 28 (ClinicalTrials.gov identifier: NCT01234519, Study ID Number: AEZS-108-046).
Conclusion
Considering the usually poor outcome of progressive UC and the short survival of these patients the effects of zoptarelin doxorubicin in this patient has been remarkable. ■
